374962
4-Guanidinobenzoic acid hydrochloride
99%
동의어(들):
4-Guanidobenzoic acid hydrochloride
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
Linear Formula:
H2NC(=NH)NHC6H4CO2H · HCl
CAS Number:
Molecular Weight:
215.64
Beilstein:
3718032
EC Number:
MDL number:
UNSPSC 코드:
12352100
PubChem Substance ID:
NACRES:
NA.22
양식:
solid
분석:
99%
추천 제품
분석
99%
양식
solid
mp
285 °C (dec.) (lit.)
저장 온도
2-8°C
SMILES string
Cl[H].NC(=N)Nc1ccc(cc1)C(O)=O
InChI
1S/C8H9N3O2.ClH/c9-8(10)11-6-3-1-5(2-4-6)7(12)13;/h1-4H,(H,12,13)(H4,9,10,11);1H
InChI key
YETFLAUJROGBMC-UHFFFAOYSA-N
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
4-Guanidinobenzoic acid hydrochloride is a guanidine derivative. Quality standard of 4-guanidinobenzoic acid hydrochloride has been investigated.
애플리케이션
4-Guanidinobenzoic acid hydrochloride may be used in ELISA inhibition assay of mouse antiserum. It may be used in the synthesis of human acrosin inhibitor 4′-acetaminophenyl 4-guanidinobenzoate hydrochloride.2
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
이미 열람한 고객
S Ookawara et al.
European journal of clinical pharmacology, 51(2), 149-151 (1996-01-01)
Nafamostat mesilate, a potent protease inhibitor, is widely used for the treatment of pancreatitis, disseminated intravascular coagulation and as an anticoagulant in haemodialysis. However, hyperkalaemia associated with nafamostat mesilate has been reported. It is thought to be due to decreased
M K Ramjee et al.
Thrombosis research, 98(6), 559-569 (2000-07-19)
Nafamostat mesilate (FUT-175), a synthetic serine protease inhibitor, is active against a number of the serine proteases involved in coagulation. This has been proposed as the basis of its anticoagulant activity. We investigated the reaction of Nafamostat with bovine pancreatic
I Midgley et al.
Xenobiotica; the fate of foreign compounds in biological systems, 24(1), 79-92 (1994-01-01)
1. The metabolic fate of N,N-dimethylcarbamoylmethyl 4-(4-guanidino[14C]benzoyloxy)phenylacetate methanesulphonate (14C-camostat mesylate) was investigated after i.v. administration to man (12-h infusion), and to rat and dog (bolus injection). 2. Renal excretion (mainly in 24 h) accounted for at least 80% dose in
Di-ya L, et al.
Chinese Pharmaceutical Journal, 3, 28-28 (2010)
S Muto et al.
British journal of pharmacology, 111(1), 173-178 (1994-01-01)
1. The present experiments were undertaken to determine the mechanism(s) of hyperkalaemia caused by nafamostat mesilate (NM), a serine-protease inhibitor. 2. We investigated the effects of luminal addition of two metabolites of NM, p-guanidinobenzoic acid (PGBA) and 6-amidino-2-naphthol (AN), on
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.